Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.525
Journals
Pharmaceutics
Special Issues
Pediatric Drug Formulations
share announcement

Special Issue "Pediatric Drug Formulations"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 30 September 2023 | Viewed by 802

Special Issue Editor

Dr. Sofia Mattsson

E-Mail Website
Guest Editor
Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden
Interests: pharmaceutics; drug delivery; pediatric dosage forms; drug formulation; solid oral dosage forms; drug release; powder mixtures

Special Issue Information

Dear Colleagues,

There is an increasing demand for personalized medicines and treatments to be able to meet the needs of each patient and improve drug treatment. This includes drug treatments for the pediatric population. Consequently, there is a considerable need to develop medicines and dosage forms suitable for the pediatric population to ensure the safe and effective administration of drugs to children. The off-label use of drugs in pediatric patients is common but may require doses that differ from those of adults; furthermore, the administration of inappropriate dosage forms leads to unsafe drug use and decreased compliance. A suitable dosage form for children should possess convenient administration (including palatability and avoiding manipulation pre-administration), flexibility in dosing, and safety.

The aim of this Special Issue is to shed light on the development of pediatric drug formulations in the scientific community and to highlight the research in this important area.

Dr. Sofia Mattsson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric
  • children
  • drug formulation
  • dosage form
  • administration
  • safety
  • flexible dosing
  • compliance
  • excipients

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Article
Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants
by
Hardik Chandasana
,
Ryan Marnoch
,
Michael McKenna
,
Julia Double
,
Ciara Seal
,
Gilda Bontempo
,
Allen Wolstenholme
and
Ann Buchanan
Pharmaceutics 2023, 15(5), 1470; https://doi.org/10.3390/pharmaceutics15051470 - 11 May 2023
Viewed by 503
Abstract
This randomized food effect study in healthy adult participants examined dispersible tablet formulations of fixed-dose combinations of dolutegravir/abacavir/lamivudine (TRIUMEQ) and dolutegravir/lamivudine (DOVATO). While adult tablet formulations of these combinations are currently approved for the treatment of human immunodeficiency virus, alternate formulations for children [...] Read more.
This randomized food effect study in healthy adult participants examined dispersible tablet formulations of fixed-dose combinations of dolutegravir/abacavir/lamivudine (TRIUMEQ) and dolutegravir/lamivudine (DOVATO). While adult tablet formulations of these combinations are currently approved for the treatment of human immunodeficiency virus, alternate formulations for children are urgently needed to facilitate appropriate pediatric dosing for patients who may have difficulty swallowing a conventional tablet. This study compared the effect of a high-fat, high-calorie meal on the pharmacokinetics, safety, and tolerability of dispersible tablet (DT) formulations of the two-drug and three-drug regimens, with administration under fasting conditions. Both the two-drug and three-drug dispersible tablet formulations, administered under fasting conditions and following a high-fat, high-calorie meal, were well tolerated in healthy participants. There were no clinically relevant differences in drug exposure for either regimen when administered with a high-fat meal as compared to under fasting conditions. Safety observations were similar for both treatments, either in the fed or fasted state. Both TRIUMEQ DT and DOVATO DT formulations can be administer with or without food. Full article
(This article belongs to the Special Issue Pediatric Drug Formulations)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop